Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant (Q39433256)

11 September 2017

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant (English)

1 reference

11 September 2017

phase I clinical trial

0 references

0 references

1 reference

1 reference

1

1 reference

11 September 2017

11

Anders RF

1 reference

11 September 2017

12

Brown GV

1 reference

11 September 2017

Lawrence G

2

1 reference

11 September 2017

Smillie A

3

1 reference

11 September 2017

Rzepczyk CM

4

1 reference

11 September 2017

Reed C

5

1 reference

11 September 2017

Taylor D

6

1 reference

11 September 2017

Anderson K

7

1 reference

11 September 2017

Stowers A

8

1 reference

11 September 2017

Kemp R

9

1 reference

11 September 2017

Allworth A

10

1 reference

11 September 2017

Pye D

13

1 reference

11 September 2017

Schoofs P

14

1 reference

11 September 2017

Irving DO

15

1 reference

11 September 2017

Dyer SL

16

1 reference

11 September 2017

Woodrow GC

17

1 reference

11 September 2017

Briggs WR

18

1 reference

11 September 2017

Reber R

19

1 reference

11 September 2017

Stürchler D

20

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

11 September 2017

1 reference

11 September 2017

17

1 reference

11 September 2017

3145-3159

1 reference

11 September 2017

23-24

1 reference

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Immunization against blood-stage rodent malaria using purified parasite antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Mapping of the region predominantly recognized by antibodies to the Plasmodium falciparum merozoite surface antigen MSA 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Immunization against malaria with a recombinant protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

A protective monoclonal antibody recognizes a linear epitope in the precursor to the major merozoite antigens of Plasmodium chabaudi adami.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

A second region recognized by the protective monoclonal antibody 5C10/66 in the precursor to the major merozoite surface antigen of Plasmodium chabaudi adami.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

An epitope recognised by inhibitory monoclonal antibodies that react with a 51 kilodalton merozoite surface antigen in Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Cross-reactivity of antibody against an epitope of the Plasmodium falciparum second merozoite surface antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Structural diversity in the Plasmodium falciparum merozoite surface antigen 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Plasmodium falciparum ring-infected erythrocyte surface antigen is released from merozoite dense granules after erythrocyte invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf 155, react with the native protein and inhibit merozoite invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Association between cellular response (IL-4) to RESA/Pf155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Selection of an adjuvant for vaccination with the malaria antigen, MSA-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Structure of the RESA gene of Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

A simplification of the protein assay method of Lowry et al. which is more generally applicable

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Kinetic constraints on the development of a malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2899%2900175-9

7 January 2021

10.1016/S0264-410X(99)00175-9

Identifiers

DOI

1 reference

11 September 2017

1 reference